Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut du Cancer de Montpellier - Val d'Aurelle
AIDS Malignancy Consortium
Eastern Cooperative Oncology Group
Duke University
Instituto do Cancer do Estado de São Paulo
University of California, San Francisco
AHS Cancer Control Alberta
Karolinska Institutet
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Tata Memorial Centre
Centre Hospitalier Universitaire de Besancon
University of Sao Paulo
Sun Yat-sen University
M.D. Anderson Cancer Center
Institut de cancérologie Strasbourg Europe
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Centre Hospitalier Universitaire de Besancon
Sixth Affiliated Hospital, Sun Yat-sen University
Centre Hospitalier Universitaire de Besancon
UNICANCER
Centre Hospitalier Universitaire de Besancon
Radiation Therapy Oncology Group
Sixth Affiliated Hospital, Sun Yat-sen University
Institut Paoli-Calmettes
Radiation Therapy Oncology Group
AHS Cancer Control Alberta
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)